Transforming science into health
TECHNOLOGY
ImunoTera offers an unprecedented biotech platform capable of restoring and activating immune system functions.
The platform, called Act-Tera, is based on a recombinant protein designed with high therapeutic precision to fight different types of cancer.
Our first product, the TERAH-7 protein, targets precancerous lesions and cancer related to the human papilloma virus, HPV. How it works:
The Act-Tera platform is versatile and works as a therapeutic vaccine, which can be applied by different immunological strategies.
OUR PLATFORM
.png)
MECHANISMS OF ACTION
With 100% Brazilian technology, the therapeutic vaccine increases the body's natural defenses against cancer, through three mechanisms:
.jpeg)
EFFICACY
ImunoTera's therapeutic vaccine showed synergism with other treatments, such as chemotherapy, with high efficacy in fighting HPV-induced cancer in the pre-clinical phase.
WHO WE ARE
Luana Raposo de Melo
Industrial Pharmacist (UFF)
Master's Degree in Biological Sciences (USP)
Doctorate in Biological Sciences (USP)
MBA in Health Innovation Management
The Science and Business of Biotechnology (MIT)
Bruna Maldonado Porchia
Biologist (UNESP)
Master's Degree in Biotechnology (USP)
Doctorate in Biological Sciences (USP)
Postdoctoral Immunology (USP)
Clinical Research Specialization (Invitare)
Mariana de Oliveira Diniz
Biologist (USP)
Doctorate in Biotechnology (USP/U. Penn., USA)
Postdoctoral Biological Sciences (USP)
Postdoctoral (Université Paris-Descartes)
Postdoctoral (University College London)
Timeline
Events and Awards
